$SBFM
Sunshine Biopharma Inc. Stock $sbfm

$sbfm Overview Financials Valuation SEC Filings Company Website

2023 Q3 Form 10-Q Financial Statement

#000168316823005518 Filed on August 10, 2023

Income Statement

Concept	2023 Q3	2023 Q2	2022 Q2
Revenue	$5.958M	$5.561M	$150.3K
YoY Change	4385.93%	3599.67%	184.27%
Cost Of Revenue	$3.967M	$3.608M	$74.68K
YoY Change	5931.06%	4731.24%	303.36%
Gross Profit	$1.990M	$1.953M	$75.62K
YoY Change	2869.42%	2482.18%	120.1%
Gross Profit Margin	33.41%	35.12%	50.31%
Selling, General & Admin	$3.012M	$3.076M	$723.2K
YoY Change	111.83%	325.28%	217.17%
% of Gross Profit	151.32%	157.5%	956.3%
Research & Development	$238.0K	$368.6K	$45.94K
YoY Change	-34.34%	702.22%	-76.04%
% of Gross Profit	11.96%	18.87%	60.75%
Depreciation & Amortization	$37.21K	$34.88K	$2.287K
YoY Change	4616.1%	1425.01%	-28.35%
% of Gross Profit	1.87%	1.79%	3.02%
Operating Expenses	$3.250M	$3.444M	$45.94K
YoY Change	796.45%	7396.49%	-76.04%
Operating Profit	-$779.5K	-$989.6K	-$695.8K
YoY Change	-54.63%	42.23%	79.05%
Interest Expense	$38.53K	$27.60K	$0.00
YoY Change	1926250.0%		-100.0%
% of Operating Profit
Other Income/Expense, Net	$168.9K	$175.2K	$156.9K
YoY Change	-35.26%	11.64%	-106.3%
Pretax Income	-$610.5K	-$814.4K	-$538.9K
YoY Change	-58.1%	51.14%	-81.28%
Income Tax	$40.95K	$87.68K	$0.00
% Of Pretax Income
Net Earnings	-$651.5K	-$902.1K	-$538.9K
YoY Change	-55.29%	67.41%	-81.28%
Net Earnings / Revenue	-10.94%	-16.22%	-358.51%
Basic Earnings Per Share	$0.04	-$0.02	-$0.03
Diluted Earnings Per Share	-$0.03	-$0.04	-$34.00K
COMMON SHARES
Basic Shares Outstanding	25.75M shares	22.14M shares	15.85M shares
Diluted Shares Outstanding	25.69M shares	25.35M shares	15.85M shares

Balance Sheet

Concept	2023 Q3	2023 Q2	2022 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$18.85M	$19.73M	$41.73M
YoY Change	-53.52%	-52.72%	2304.93%
Cash & Equivalents	$18.85M	$19.73M	$41.73M
Short-Term Investments
Other Short-Term Assets	$40.00K	$107.0K	$56.15K
YoY Change	14.35%	90.6%	141.19%
Inventory	$4.517M	$4.251M	$205.4K
Prepaid Expenses	$37.56K	$107.0K	$48.56K
Receivables	$2.034M	$2.011M	$24.00
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$25.43M	$26.10M	$41.99M
YoY Change	-37.75%	-37.84%	2228.1%
LONG-TERM ASSETS
Property, Plant & Equipment	$334.9K	$366.7K	$1.642K
YoY Change	8783.87%	22231.55%	-87.82%
Goodwill
YoY Change
Intangibles	$1.216M	$1.234M
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$2.215M	$2.311M	$1.642K
YoY Change	58664.59%	140662.06%	-87.82%
TOTAL ASSETS
Total Short-Term Assets	$25.43M	$26.10M	$41.99M
Total Long-Term Assets	$2.215M	$2.311M	$1.642K
Total Assets	$27.65M	$28.41M	$41.99M
YoY Change	-32.34%	-32.34%	2210.92%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.221M	$1.760M	$104.7K
YoY Change	362.48%	1581.05%	1.45%
Accrued Expenses	$120.0K	$122.2K	$0.00
YoY Change			-100.0%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$5.088M	$4.660M	$104.7K
YoY Change	959.56%	4351.82%	-83.53%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change			-100.0%
Other Long-Term Liabilities	$560.0K	$596.9K
YoY Change
Total Long-Term Liabilities	$598.7K	$639.9K	$0.00
YoY Change			-100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$5.088M	$4.660M	$104.7K
Total Long-Term Liabilities	$598.7K	$639.9K	$0.00
Total Liabilities	$5.687M	$5.300M	$104.7K
YoY Change	1084.23%	4963.07%	-96.11%
SHAREHOLDERS EQUITY
Retained Earnings	-$62.66M	-$62.00M	-$34.43M
YoY Change	74.59%	80.09%
Common Stock	$25.68K	$25.75K	$18.89K
YoY Change	35.96%	36.32%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$21.96M	$23.11M	$41.89M
YoY Change
Total Liabilities & Shareholders Equity	$27.65M	$28.41M	$41.99M
YoY Change	-32.34%	-32.34%	2210.92%

Cashflow Statement

Concept	2023 Q3	2023 Q2	2022 Q2
OPERATING ACTIVITIES
Net Income	-$651.5K	-$902.1K	-$538.9K
YoY Change	-55.29%	67.41%	-81.28%
Depreciation, Depletion And Amortization	$37.21K	$34.88K	$2.287K
YoY Change	4616.1%	1425.01%	-28.35%
Cash From Operating Activities	-$460.0K	-$3.778M	-$573.8K
YoY Change	-59.07%	558.42%	-7.28%
INVESTING ACTIVITIES
Capital Expenditures	$10.00K	$294.2K
YoY Change
Acquisitions
YoY Change
Other Investing Activities	$30.00K	$34.76K
YoY Change
Cash From Investing Activities	$20.00K	-$259.5K
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-60.00K	4.058M	29.12M
YoY Change		-86.07%	5188.97%
NET CHANGE
Cash From Operating Activities	-460.0K	-3.778M	-573.8K
Cash From Investing Activities	20.00K	-259.5K
Cash From Financing Activities	-60.00K	4.058M	29.12M
Net Change In Cash	-500.0K	20.45K	28.55M
YoY Change	-55.51%	-99.93%	-41962.01%
FREE CASH FLOW
Cash From Operating Activities	-$460.0K	-$3.778M	-$573.8K
Capital Expenditures	$10.00K	$294.2K
Free Cash Flow	-$470.0K	-$4.072M
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Entity Central Index Key EntityCentralIndexKey	0001402328
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue		usd
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2023-06-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-41282
	dei	Entity Registrant Name EntityRegistrantName	SUNSHINE BIOPHARMA, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	CO
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	20-5566275
	dei	Entity Address Address Line1 EntityAddressAddressLine1	6500 Trans-Canada Highway
	dei	Entity Address Address Line2 EntityAddressAddressLine2	4th Floor
	dei	Entity Address Address Line3 EntityAddressAddressLine3	Pointe-Claire
	dei	Entity Address City Or Town EntityAddressCityOrTown	Quebec
	dei	Entity Address Country EntityAddressCountry	CA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	H9R 0A5
	dei	City Area Code CityAreaCode	(514)
	dei	Local Phone Number LocalPhoneNumber	426-6161
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2023Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	25746302	shares
CY2023Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	19729491	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	21826437	usd
CY2023Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	2011308	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1912153	usd
CY2023Q2	us-gaap	Inventory Net InventoryNet	4250887	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	3289945	usd
CY2023Q2	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	107023	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	283799	usd
CY2023Q2	us-gaap	Assets Current AssetsCurrent	26098709	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	27312334	usd
CY2023Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	366684	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	394249	usd
CY2023Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1233570	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	776856	usd
CY2023Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	711059	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	760409	usd
CY2023Q2	us-gaap	Assets Assets	28410022	usd
CY2022Q4	us-gaap	Assets Assets	29243848	usd
CY2023Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	1759789	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2802797	usd
CY2023Q2	SBFM	Earnout Payable EarnoutPayable	2547831	usd
CY2022Q4	SBFM	Earnout Payable EarnoutPayable	3632000	usd
CY2023Q2	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	230581	usd
CY2022Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	373191	usd
CY2023Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	122146	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	123026	usd
CY2023Q2	us-gaap	Liabilities Current LiabilitiesCurrent	4660347	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	6931014	usd
CY2023Q2	us-gaap	Deferred Tax And Other Liabilities Noncurrent DeferredTaxAndOtherLiabilitiesNoncurrent	43032	usd
CY2022Q4	us-gaap	Deferred Tax And Other Liabilities Noncurrent DeferredTaxAndOtherLiabilitiesNoncurrent	43032	usd
CY2023Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	596850	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	642232	usd
CY2023Q2	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	639882	usd
CY2022Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	685264	usd
CY2023Q2	us-gaap	Liabilities Liabilities	5300229	usd
CY2022Q4	us-gaap	Liabilities Liabilities	7616278	usd
CY2023Q2	us-gaap	Preferred Stock Value PreferredStockValue	1000	usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	1000	usd
CY2023Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	3000000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	3000000000	shares
CY2023Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	25746302	shares
CY2023Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	25746302	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	22585632	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	22585632	shares
CY2023Q2	us-gaap	Common Stock Value CommonStockValue	25746	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	22585	usd
CY2023Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	84422143	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	80841752	usd
CY2023Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	665056	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	161847	usd
CY2023Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-62004152	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-59399614	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	23109793	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	21627570	usd
CY2023Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	28410022	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	29243848	usd
CY2023Q2	us-gaap	Revenues Revenues	5560865	usd
CY2022Q2	us-gaap	Revenues Revenues	150307	usd
	us-gaap	Revenues Revenues	10454918	usd
	us-gaap	Revenues Revenues	272952	usd
CY2023Q2	us-gaap	Cost Of Revenue CostOfRevenue	3608118	usd
CY2022Q2	us-gaap	Cost Of Revenue CostOfRevenue	74683	usd
	us-gaap	Cost Of Revenue CostOfRevenue	6674049	usd
	us-gaap	Cost Of Revenue CostOfRevenue	134528	usd
CY2023Q2	us-gaap	Gross Profit GrossProfit	1952747	usd
CY2022Q2	us-gaap	Gross Profit GrossProfit	75624	usd
	us-gaap	Gross Profit GrossProfit	3780869	usd
	us-gaap	Gross Profit GrossProfit	138424	usd
CY2023Q2	us-gaap	Professional Fees ProfessionalFees	75281	usd
CY2022Q2	us-gaap	Professional Fees ProfessionalFees	41060	usd
	us-gaap	Professional Fees ProfessionalFees	245031	usd
	us-gaap	Professional Fees ProfessionalFees	114860	usd
CY2023Q2	SBFM	Consulting Expense ConsultingExpense	392454	usd
CY2022Q2	SBFM	Consulting Expense ConsultingExpense	101683	usd
	SBFM	Consulting Expense ConsultingExpense	524069	usd
	SBFM	Consulting Expense ConsultingExpense	107181	usd
CY2023Q2	us-gaap	Noninterest Expense Directors Fees NoninterestExpenseDirectorsFees	100000	usd
CY2022Q2	us-gaap	Noninterest Expense Directors Fees NoninterestExpenseDirectorsFees	50000	usd
	us-gaap	Noninterest Expense Directors Fees NoninterestExpenseDirectorsFees	200000	usd
	us-gaap	Noninterest Expense Directors Fees NoninterestExpenseDirectorsFees	50000	usd
CY2023Q2	us-gaap	Legal Fees LegalFees	145815	usd
CY2022Q2	us-gaap	Legal Fees LegalFees	112360	usd
	us-gaap	Legal Fees LegalFees	259572	usd
	us-gaap	Legal Fees LegalFees	256919	usd
CY2023Q2	us-gaap	Marketing Expense MarketingExpense	133177	usd
CY2022Q2	us-gaap	Marketing Expense MarketingExpense	87680	usd
	us-gaap	Marketing Expense MarketingExpense	261090	usd
	us-gaap	Marketing Expense MarketingExpense	182720	usd
CY2023Q2	SBFM	Office Expense OfficeExpense	395385	usd
CY2022Q2	SBFM	Office Expense OfficeExpense	90407	usd
	SBFM	Office Expense OfficeExpense	877843	usd
	SBFM	Office Expense OfficeExpense	372912	usd
CY2023Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	368565	usd
CY2022Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	45943	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	801490	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	407595	usd
CY2023Q2	us-gaap	Salaries And Wages SalariesAndWages	1200167	usd
CY2022Q2	us-gaap	Salaries And Wages SalariesAndWages	240000	usd
	us-gaap	Salaries And Wages SalariesAndWages	3200424	usd
	us-gaap	Salaries And Wages SalariesAndWages	560000	usd
CY2023Q2	SBFM	Taxes Taxes	96649	usd
CY2022Q2	SBFM	Taxes Taxes	0	usd
	SBFM	Taxes Taxes	160367	usd
	SBFM	Taxes Taxes	0	usd
CY2023Q2	us-gaap	Depreciation Depreciation	34877	usd
CY2022Q2	us-gaap	Depreciation Depreciation	2287	usd
	us-gaap	Depreciation Depreciation	69587	usd
	us-gaap	Depreciation Depreciation	5397	usd
CY2023Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2942370	usd
CY2022Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	771420	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6599473	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2057584	usd
CY2023Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-989623	usd
CY2022Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-695796	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-2818604	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-1919160	usd
CY2023Q2	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-261	usd
CY2022Q2	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	29	usd
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-246	usd
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	20	usd
CY2023Q2	us-gaap	Interest Income Debt Securities Operating InterestIncomeDebtSecuritiesOperating	203049	usd
CY2022Q2	us-gaap	Interest Income Debt Securities Operating InterestIncomeDebtSecuritiesOperating	146043	usd
	us-gaap	Interest Income Debt Securities Operating InterestIncomeDebtSecuritiesOperating	416930	usd
	us-gaap	Interest Income Debt Securities Operating InterestIncomeDebtSecuritiesOperating	146046	usd
CY2023Q2	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
CY2022Q2	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	10852	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	10852	usd
CY2023Q2	us-gaap	Interest Expense InterestExpense	27596	usd
CY2022Q2	us-gaap	Interest Expense InterestExpense	-0	usd
	us-gaap	Interest Expense InterestExpense	68671	usd
	us-gaap	Interest Expense InterestExpense	12864	usd
CY2023Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	175192	usd
CY2022Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	156924	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	348013	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	144054	usd
CY2023Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-814431	usd
CY2022Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-538872	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-2470591	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1775106	usd
CY2023Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	87677	usd
CY2022Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-0	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	133947	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-0	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-902108	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-538872	usd
	us-gaap	Net Income Loss NetIncomeLoss	-2604538	usd
	us-gaap	Net Income Loss NetIncomeLoss	-1775106	usd
CY2023Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Before Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax	492049	usd
CY2022Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Before Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax	-12645	usd
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Before Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax	503209	usd
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Before Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax	-11638	usd
CY2023Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-410059	usd
CY2022Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-551517	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-2101329	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-1786744	usd
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.02
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.03
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.09
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.18
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	25350263	shares
CY2023Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	25350263	shares
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	15849518	shares
CY2022Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	15849518	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	23827205	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	23827205	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	9691625	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	9691625	shares
	us-gaap	Net Income Loss NetIncomeLoss	-2604538	usd
	us-gaap	Net Income Loss NetIncomeLoss	-1775106	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	69594	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	5397	usd
	us-gaap	Unrealized Gain Loss On Foreign Currency Derivatives Net Before Tax UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax	-0	usd
	us-gaap	Unrealized Gain Loss On Foreign Currency Derivatives Net Before Tax UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax	20	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-0	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	10852	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	55160	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-7774	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	885243	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	99721	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-182852	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	18937	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-1103502	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	61742	usd
	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	-147980	usd
	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	0	usd
	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	-1084169	usd
	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	-48287	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-5628146	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1878010	usd
	SBFM	Reduction In Right Of Use Asset ReductionInRightOfUseAsset	66846	usd
	SBFM	Reduction In Right Of Use Asset ReductionInRightOfUseAsset	0	usd
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	17645	usd
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	-0	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	454980	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	-0	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-405779	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	0	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	4089208	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	43560363	usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	1156	usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	usd
	SBFM	Purchase Of Treasury Stock PurchaseOfTreasuryStock	506822	usd
	SBFM	Purchase Of Treasury Stock PurchaseOfTreasuryStock	99000	usd
	SBFM	Payment For Lease Liability PaymentForLeaseLiability	63870	usd
	SBFM	Payment For Lease Liability PaymentForLeaseLiability	-0	usd
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	-0	usd
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	1900000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	3519672	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	41561363	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	21826437	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2045167	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-2514253	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	39683353	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	9	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-12383	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	417298	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	11638	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	19729491	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	41727775	usd
	us-gaap	Interest Paid Net InterestPaidNet	0	usd
	us-gaap	Interest Paid Net InterestPaidNet	61151	usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	19429478	usd
CY2023Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	4089218	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	1156	usd
CY2023Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-410059	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	23109793	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	21627570	usd
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	4089218	usd
	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	1156	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-2101329	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	23109793	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	13314108	usd
CY2022Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	16752915	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	12370774	usd
CY2022Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-551517	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	41886280	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	211662	usd
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	30367185	usd
	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	13193177	usd
	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	99000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-1786744	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	41886280	usd
CY2022	us-gaap	Business Acquisitions Pro Forma Revenue BusinessAcquisitionsProFormaRevenue	14758115	usd
CY2021	us-gaap	Business Acquisitions Pro Forma Revenue BusinessAcquisitionsProFormaRevenue	7927165	usd
CY2022	us-gaap	Business Acquisitions Pro Forma Income Loss From Continuing Operations Before Changes In Accounting And Extraordinary Items Net Of Tax BusinessAcquisitionsProFormaIncomeLossFromContinuingOperationsBeforeChangesInAccountingAndExtraordinaryItemsNetOfTax	-26192503	usd
CY2021	us-gaap	Business Acquisitions Pro Forma Income Loss From Continuing Operations Before Changes In Accounting And Extraordinary Items Net Of Tax BusinessAcquisitionsProFormaIncomeLossFromContinuingOperationsBeforeChangesInAccountingAndExtraordinaryItemsNetOfTax	-2224253	usd
CY2022	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	-26164764	usd
CY2021	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	-12289655	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	948240	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Period Increase Decrease FiniteLivedIntangibleAssetsPeriodIncreaseDecrease	305801	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	1254041	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	20471	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1233570	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	776856	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Period Increase Decrease FiniteLivedIntangibleAssetsPeriodIncreaseDecrease	183760	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	960616	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	12376	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	948240	usd
CY2023Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	7853	usd
CY2023Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	8096	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	46814	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	46814	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	45611	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	6153	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	1989	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	112463	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	105930	usd
CY2023Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	3000000000	shares
CY2023Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	30000000	shares
CY2023Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.10
CY2023Q1	us-gaap	Stock Repurchase Program Authorized Amount1 StockRepurchaseProgramAuthorizedAmount1	2000000	usd
	us-gaap	Dividends Dividends	0	usd
CY2023Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	711059	usd
CY2023Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	122146	usd
CY2023Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	596850	usd
CY2023Q2	SBFM	Lessee Operating Lease Remaining Lease Term1 LesseeOperatingLeaseRemainingLeaseTerm1	6 years 6 months
CY2023Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.06	pure
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	61987	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	118545	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	118737	usd
CY2023Q2	SBFM	Lessee Operating Lease Liability Payments Due After Year Four LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour	201335	usd
CY2023Q2	us-gaap	Salaries Wages And Officers Compensation SalariesWagesAndOfficersCompensation	225000	usd
CY2022Q2	us-gaap	Salaries Wages And Officers Compensation SalariesWagesAndOfficersCompensation	240000	usd
	us-gaap	Salaries Wages And Officers Compensation SalariesWagesAndOfficersCompensation	1045000	usd
	us-gaap	Salaries Wages And Officers Compensation SalariesWagesAndOfficersCompensation	510000	usd
CY2023Q2	us-gaap	Noninterest Expense Directors Fees NoninterestExpenseDirectorsFees	100000	usd
CY2022Q2	us-gaap	Noninterest Expense Directors Fees NoninterestExpenseDirectorsFees	50000	usd
	us-gaap	Noninterest Expense Directors Fees NoninterestExpenseDirectorsFees	200000	usd
	us-gaap	Noninterest Expense Directors Fees NoninterestExpenseDirectorsFees	50000	usd

Files In Submission

Name	View Source	Status
0001683168-23-005518-index-headers.html	Edgar Link	pending
0001683168-23-005518-index.html	Edgar Link	pending
0001683168-23-005518.txt	Edgar Link	pending
0001683168-23-005518-xbrl.zip	Edgar Link	pending
adva-27a.jpg	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
sbfm-20230630.xsd	Edgar Link	pending
Show.js	Edgar Link	pending
sunshinelogo.jpg	Edgar Link	pending
sunshine_ex3101.htm	Edgar Link	pending
sunshine_ex3102.htm	Edgar Link	pending
sunshine_ex3201.htm	Edgar Link	pending
sunshine_i10q-063023.htm	Edgar Link	pending
sbfm-20230630_pre.xml	Edgar Link	unprocessable
sbfm-20230630_lab.xml	Edgar Link	unprocessable
sunshine_i10q-063023_htm.xml	Edgar Link	completed
sbfm-20230630_cal.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
sbfm-20230630_def.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$SBFM
Sunshine Biopharma Inc. Stock $sbfm

2023 Q3 Form 10-Q Financial Statement

#000168316823005518 Filed on August 10, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SBFM Sunshine Biopharma Inc. Stock $sbfm

2023 Q3 Form 10-Q Financial Statement

#000168316823005518 Filed on August 10, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SBFM
Sunshine Biopharma Inc. Stock $sbfm